Novo Nordisk is working on a new obesity drug that could help patients shed more than any other weight-loss drug on the ...

With nearly $14 billion sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, ...

MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access. Novo Nordisk's production shift raises concerns as diabetes cases rise, ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Disruptive analytics’ Substack by Magnus Ofstad. In this article ...

Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and ...

Danish drugmaker Novo Nordisk's shares hit an over 9-month low on Thursday after surging more than 8% the previous day, as ...

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

After rising in premarket trading, Novo Nordisk's U.S.-listed shares fell after the market opened Wednesday as its ...

Novo Nordisk, the pharma giant behind Ozempic and Wegovy, has surprising love story origins. The founders, a married couple, ...

Novo Nordisk and Eli Lilly are both raking in billions from their blockbuster weight loss drugs that are also approved to ...

Analyst Michael Nedelcovych from TD Cowen maintained a Buy rating on Novo Nordisk (NVO – Research Report) and keeping the price target at ...